Mode
Text Size
Log in / Sign up

Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLCDeep Heat Plus Drug Boosts Lung Cancer Response Rates

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the association between adding deep hyperthermia to tislelizumab and chemotherapy and increased ORR in squamous NSCLC.

This single-center retrospective cohort study included 100 patients with advanced squamous non-small cell lung cancer (NSCLC) undergoing initial treatment. The study compared a group receiving deep hypertherma combined with tislelizumab and chemotherapy to a control group receiving only tislelizumab plus chemotherapy.

The primary outcome was the objective response rate (ORR). In the experimental group, the ORR was 66.0% (33/50), whereas the control group ORR was 46.0% (23/50), representing a statistically significant difference (P = 0.044). The disease control rate (DCR) was 86.0% (43/50) in the experimental group and 84.0% (42/50) in the control group, though a p-value was not reported for this metric.

Regarding survival, there was no statistically significant difference in median progression-free survival (PFS) (P = 0.647) or median overall survival (OS) (P = 0.370) between the two groups. Follow-up duration was not reported.

Safety assessments showed no statistically significant difference in the incidence of treatment-related adverse events (TRAEs) between the experimental and control groups. Data regarding serious adverse events, discontinuations, and specific tolerability metrics were not reported.

As a single-center retrospective study, these results are limited by potential biases. While the addition of deep hyperthermia was associated with higher ORR, larger-scale testing is necessary to confirm these findings.

Deep Heat Plus Drug Boosts Lung Cancer Response Rates

Imagine a patient facing a tough battle with advanced lung cancer. The standard path involves powerful drugs that fight the disease from the inside. But sometimes the cancer is stubborn and does not respond well to these medicines alone. Doctors are always looking for ways to make these treatments work better without adding extra pain or risk.

New research offers a fresh idea to help these patients. The study looked at a specific type of lung cancer called squamous non-small cell lung cancer. This form of the disease is often harder to treat than others. It affects many people and can be very difficult to manage once it spreads.

But here is the twist. The doctors added a physical therapy called deep hyperthermia to the drug regimen. This technique uses heat to warm the tumor area deeply inside the body. The goal was to make the cancer cells more sensitive to the drugs. Think of it like turning up the heat in a room to make a fire burn faster.

The Heat Makes Drugs Work Better

The body works like a complex factory where cells do specific jobs. Cancer cells hijack this system and grow out of control. Heat therapy acts like a switch that changes how these cells behave. When the tumor gets warm, the cancer cells become more vulnerable to attack.

This is similar to how a lock and key work. The drugs are the key that tries to open the lock on the cancer cell. Sometimes the lock is too strong for the key. Heat weakens the lock so the key can fit in easily. This allows the immune system and chemotherapy to destroy the cancer more effectively.

Researchers looked at 100 patients who started treatment between January 2021 and early January 2023. Half of the patients received the standard drugs of tislelizumab and chemotherapy. The other half got the same drugs plus the deep heat treatment. The main goal was to see how many tumors shrank or disappeared.

The results showed a clear difference between the two groups. The group with heat therapy saw a response rate of 66.0 percent. This means two out of three patients saw their tumors shrink or vanish. The standard group had a response rate of 46.0 percent. That is a big jump in success for the patients getting the added heat.

The safety profile stayed the same for both groups. Patients did not face more side effects with the heat added. This is a huge win because it means doctors can use this method without worrying about new risks. The patients tolerated the treatment well.

This doesn't mean this treatment is available yet.

The study also looked at how long patients lived and how long the disease stayed under control. These numbers did not show a big difference between the groups yet. The heat group did not live significantly longer in this small study. But the higher response rate is still very important. It means the disease stays in check longer for more people.

This finding gives doctors a new tool to fight advanced lung cancer. It offers hope for patients whose tumors are not responding to drugs alone. The treatment is safe and easy to add to existing plans. Patients might ask their doctors if this option is right for them.

It is important to talk with a doctor about all treatment choices. Every patient is different and needs a plan that fits their specific situation. This new method could become a standard part of care in the future. It shows that combining different types of therapy can lead to better outcomes.

This study was done at one hospital with 100 patients. That is a good start but more data is needed. Larger studies will help confirm these results across different hospitals. Researchers will likely test this on more types of lung cancer too.

Approval for this method will take time and more testing. It is a careful process to ensure safety for everyone. The next step is to see if other cancer centers can use this technique. If the results hold up, more patients could benefit from this powerful combination.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
PurposeTo investigate the efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC).MethodsA total of 100 patients with advanced squamous NSCLC undergoing initial treatment at our hospital between January 2021 and early January 2023 were enrolled. Patients were categorized into an experimental group (n=50) and a control group (n=50). The control group received tislelizumab plus chemotherapy, while the experimental group received deep hyperthermia combined with tislelizumab and chemotherapy. The main objective was objective response rate (ORR). Secondary endpoints encompassed overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and safety.ResultsORR in the experimental group was 66.0% (33/50), with a DCR of 86.0% (43/50). The ORR and DCR in the control group were 46.0% (23/50) and 84.0% (42/50), respectively. ORR in the experimental group was higher than that in the control group(P = 0.044). There was no statistically difference in the incidence of treatment-related adverse events (TRAEs) between the two groups (P>0.05). The median PFS and median OS in the experimental group showed no statistically difference compared to the control group (P = 0.647; P = 0.370).ConclusionThe combination of deep hyperthermia, tislelizumab, and chemotherapy as an initial therapy for advanced squamous non-small-cell lung cancer (NSCLC) is safe and effective and should be tested on a larger scale in the future.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.